 2021 Earnings Call Summary

The transcript highlights the financial performance of a company in the healthcare industry during the COVID-19 pandemic. The company's proven business model and adaptable strategy have allowed it to continue delivering consistent results and long-term growth. The company has focused on growing categories and connecting with consumers through brand building efforts, resulting in strong revenue and earnings performance. The company's brand, Compound W, is a great example of this strategy, having grown at a double-digit compound annual rate over the past five years and solidifying its position as the number one brand for wart treatment. The company's diverse portfolio and broad channel diversity have also contributed to its stable revenue performance. The company has a total gross margin of 58.2% in the first nine months and anticipates a gross margin of about 58% for the remainder of the year. The company has generated strong free cash flow and anticipates full year 2021 free cash flow at or above prior year levels. The company continues to prioritize debt reduction while balancing other disciplined capital allocation efforts to drive shareholder value.